MyHealthChecked PLC (GB:FORF)
LSE:FORF
Want to see GB:FORF full AI Analyst Report?
Top Page
MyHealthChecked PLC
(LSE:FORF)
Select Model
Select Model
Rating:45Neutral
Price Target:
8.00 p
Action:ReiteratedDate:04/24/26
The score is held down primarily by sharply weakened fundamentals—revenue collapsing to effectively zero in 2025, multi-year losses, and negative operating/free cash flow despite low leverage. Technicals add some near-term support via positive momentum and price above short-term averages, but overbought readings and a negative earnings-based valuation (negative P/E) keep the overall score in the low range.
Positive Factors
Low financial leverage
The balance sheet shows minimal debt and effectively zero debt-to-equity, giving the company low interest burden and financial flexibility. This conservatism provides runway and optionality to raise funds or restructure operations while working to restore revenue over the next months.
Negative Factors
Severe revenue collapse
A near-total revenue collapse destroys scale economics and long-term customer relationships. Loss of top-line revenue impairs fixed-cost absorption, pricing leverage and supplier terms, making multi-month recovery challenging and increasing execution risk to rebuild sustainable demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
The balance sheet shows minimal debt and effectively zero debt-to-equity, giving the company low interest burden and financial flexibility. This conservatism provides runway and optionality to raise funds or restructure operations while working to restore revenue over the next months.
Read all positive factors
MyHealthChecked PLC (FORF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.92M
Dividend YieldN/A
Average Volume (3M)35.18K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth-65.72%
EPS Growth-86.57%
CountryUK
Employees14
SectorFinancial
Sector Strength70
IndustryShell Companies
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,548,767
10 Day Avg. Volume35,100
30 Day Avg. Volume35,181
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-2.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MyHealthChecked PLC Business Overview & Revenue Model
Company Description
Fortis Frontier PLC develops, distributes, and commercializes at-home healthcare and wellness tests in the United Kingdom. The company offers general health and energy profile blood test, bowel health rapid test, and stomach ulcer rapid test; nutr...
How the Company Makes Money
null...
MyHealthChecked PLC Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.58M | 0.00 | 3.61M | 10.98M | 22.31M | 16.38M |
| Gross Profit | -392.00K | -215.00K | -194.00K | 2.05M | 4.79M | 5.13M |
| EBITDA | -2.10M | -360.00K | -1.53M | 30.00K | 1.74M | 2.16M |
| Net Income | -2.24M | -1.63M | -1.79M | -159.00K | 1.52M | 2.00M |
Balance Sheet | ||||||
| Total Assets | 8.41M | 7.53M | 8.80M | 13.34M | 11.43M | 11.67M |
| Cash, Cash Equivalents and Short-Term Investments | 5.06M | 5.76M | 5.47M | 7.75M | 7.61M | 6.39M |
| Total Debt | 0.00 | 0.00 | 0.00 | 26.00K | 53.00K | 0.00 |
| Total Liabilities | 2.78M | 2.15M | 1.83M | 4.64M | 2.58M | 4.55M |
| Stockholders Equity | 5.63M | 5.38M | 6.97M | 8.70M | 8.85M | 7.11M |
Cash Flow | ||||||
| Free Cash Flow | -1.19M | -1.62M | -2.26M | 157.00K | 1.27M | 2.77M |
| Operating Cash Flow | -1.16M | -1.62M | -2.16M | 724.00K | 1.61M | 3.01M |
| Investing Cash Flow | -103.00K | 1.91M | -93.00K | -531.00K | -338.00K | -299.00K |
| Financing Cash Flow | -13.50K | 0.00 | -23.00K | -52.00K | -47.00K | 3.21M |
MyHealthChecked PLC Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
59 Neutral | £114.30M | 55.78 | 3.01% | ― | 2.73% | -65.94% | |
52 Neutral | £12.10M | 3.60 | 0.08% | ― | ― | ― | |
52 Neutral | £26.54M | -18.39 | -69.35% | ― | 31.78% | 10.27% | |
51 Neutral | £4.20M | -4.69 | -16.78% | ― | -2.87% | 52.38% | |
48 Neutral | £52.07M | 0.83 | 32.72% | ― | ― | ― | |
45 Neutral | £2.92M | -2.39 | -34.26% | ― | -65.72% | -86.57% |
* Financial Sector Average
GB:FORF
MyHealthChecked PLC
8.50
-5.50
-39.29%
GB:RUA
RUA Life Sciences
19.50
7.88
67.74%
GB:CREO
Creo Medical
12.63
1.88
17.44%
GB:EKF
EKF Diagnostics Holdings
26.55
5.55
26.43%
GB:IHC
Inspiration Healthcare
29.60
12.35
71.59%
GB:SUN
Surgical Innovations
0.45
-0.15
-25.00%
MyHealthChecked PLC Corporate Events
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Fortis Frontier Cuts Share Capital with Buyback and Cancellation
Neutral
Apr 23, 2026
Fortis Frontier PLC has executed a share buyback of 1,234,442 ordinary shares at 8.6p per share, representing about 2.42% of its issued share capital, under an authority granted at its 2025 AGM. The company plans to cancel these shares, which will...
Business Operations and StrategyStock Buyback
Fortis Frontier Cuts Share Count with Buyback as Cash Shell Reviews Strategy
Positive
Apr 23, 2026
Fortis Frontier PLC, an AIM-listed cash shell that divested its diagnostics business and rebranded from MyHealthChecked, is currently evaluating strategic avenues to enhance shareholder returns after becoming an AIM Rule 15 cash shell in late 2025...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Fortis Frontier Cuts Share Capital with Modest Buyback
Positive
Apr 16, 2026
Fortis Frontier PLC, an AIM Rule 15 cash shell formerly known as MyHealthChecked PLC, shifted to its current structure after selling its diagnostics subsidiary Concepta Diagnostics Limited in 2025 and is now assessing strategic routes to enhance s...
Business Operations and StrategyStock BuybackShareholder Meetings
Fortis Frontier Seeks Shareholder Approval for £1.23m Related-Party Buyback
Positive
Apr 1, 2026
Fortis Frontier PLC has published a circular convening a general meeting on 28 April 2026, where independent shareholders will be asked to approve two related-party share buyback agreements with substantial shareholder Mercia. The company plans to...
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A TransactionsShareholder Meetings
Fortis Frontier Reinvents Itself as Cash Shell After Diagnostics Sale
Neutral
Mar 19, 2026
Fortis Frontier PLC, an AIM-quoted cash shell formerly known as MyHealthChecked PLC, has transitioned away from its previous at-home diagnostics operations following the sale of Concepta Diagnostics Limited to Boots UK for £2.375m. As a resul...
Business Operations and StrategyStock Buyback
Fortis Frontier Buys Back Shares and Appoints New Broker as Cash Shell
Positive
Feb 9, 2026
Fortis Frontier PLC, an AIM-quoted cash shell that formerly operated as diagnostics group MyHealthChecked PLC, has no active trading business following the sale of its subsidiary Concepta Diagnostics and is focused on identifying new strategic opp...
Business Operations and StrategyStock Buyback
Fortis Frontier Tightens Share Base Ahead of Strategic Pivot
Positive
Feb 4, 2026
Fortis Frontier repurchased 250,000 shares at 8p each on 3 February 2026 under its AGM authority, with the shares to be cancelled, reducing total voting rights to 51,685,827 once treasury shares are extinguished, a move that narrows the capital ba...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.